New York, United States, June 06, 2022 (GLOBE NEWSWIRE) -- Metastatic breast cancer is another word for the advanced form of breast cancer. Breast cancer is a kind of disease in which the breast cells get uncontrollably large. Sometimes, breast cancer can spread from the breast to various other body parts, most often to the lungs, bones, liver, or brain. This is called advanced breast cancer. Based on type, the chemotherapy segment held the biggest share of the total Metastatic Breast Cancer Treatment Market at around 28.8%. Based on the region, North America held the maximum market share of about 46.72% in 2020. On the other end, the Asia Pacific region is expected to develop at the fastest CAGR over the forecasted period.
To get a first-hand overview of the report, Request a Sample at
https://www.strategicmarketresearch.com/request-sample/metastatic-breast-cancer-treatment-market
The market segmentation of the latest report published by Strategic Market Research on the Metastatic Breast Cancer Treatment Market is as follows:
Based on Types
- Chemotherapy
- Radiation Therapy
- Biologic Targeted Therapy
- Breast Surgery
- Hormone Therapy
Based on End-User
- Hospitals
- Clinics
- Other
Regions
- North America
- Europe
- Asia-Pacific
- LAMEA
Make a Direct Purchase of the latest Metastatic Breast Cancer Treatment Market Report published in the month of June 2022. Click the below link to initiate the purchase:
https://www.strategicmarketresearch.com/buy-now/metastatic-breast-cancer-treatment-market
| Report Coverage | Details |
| Forecast Period | 2020-2030. |
| Forecast Period 2020 to 2030 CAGR | 10.4 %. |
| 2030 Value Projection | USD 41.74 billion. |
| Base Year | 2020. |
| Market Size in 2020 | USD 15.52 billion. |
| Historical Data for | 2015 – 2019. |
| No. of Pages | 135. |
| Companies | Gilead Sciences,AstraZeneca,Bayer,Sun Pharmaceutical,Eli Lilly,Pfizer,Novartis,Merck,Roche,GlaxoSmithKline,Johnson & Johnson. |
| Leading Segment Based on Types | radiation therapy and chemotherapy. |
| Leading Region | North America. |
| Segments covered | Based on Types, Based on End-User, Based on Region and North America. |
| Growth Drivers | R&D initiatives, Efficient drugs to treat breast cancer and Advanced therapeutics. |
The market for Metastatic Breast Cancer Treatment is predicted to reach a market value of USD 41.74 Billion by 2030 from USD 15.52 billion in 2020, at a CAGR of 10.4 % during the forecasted period. A surge in breast cancer patients has escalated the demand for better screening, therapy, and diagnosis. Breast cancer is primarily diagnosed most frequently among American women. As per breastcancer.org, in the year 2022, it is anticipated that approximately 30% of the newly discovered cancer cases in women accounts for breast cancers. Furthermore, as of 2021, breast cancer was the most prevalent type of cancer worldwide, accounting for around 12% of all new cancer cases. Moreover, the extensive R&D activities to achieve effective Breast Cancer Therapeutic Solutions and the increasing number of patients with Breast Cancer are driving the market growth exponentially.
By type, the chemotherapy segment held the largest share of the Metastatic Breast Cancer Treatment Market.
Based on the type, the entire market is classified into Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, and Hormone Therapy. Among these segments, the chemotherapy segment held the biggest share of the total Metastatic Breast Cancer Treatment Market of around 28.8%. Chemotherapy is the most common treatment for metastatic breast cancer since it plays a vital role in slowing the total process of the tumor's growth. According to Cancer World publication magazine, the number of patients requiring first-line chemotherapy was about 9.8 Mn in 2018 and is estimated to reach 15 Mn by the end of 2040. Moreover, the total number of patients requiring first-line chemotherapy is more likely to rise by 53%. 67% of these patients (equivalent to 10.1 million) will live in developing and poor countries by the end of 2040.
By end-users, the Hospital segment possessed the highest share of the total Metastatic Breast Cancer Treatment Market.
Based on the end-users, the total market is divided into Hospitals, Clinics, and Others. Among these market segments, the hospital's market segment possessed the largest share of the entire metastatic Breast Cancer Treatment Market. Due to the growing number of hospitals in developing countries and the wide availability of various medical treatment equipment and drugs, the hospital segment dominates the global industry and is prevised to sustain its dominance throughout the forecasted period.
According to AHRQ, there were around 2.8 million cancer-related adult nonmaternal hospitalizations. Out of these cases, approximately 1.0 million stays had cancer as the principal diagnosis and comprises of an aggregate cost of around USD 23.0 billion, accounting for 6.2 % of the total adult nonmaternal inpatient hospital costs.
On average, the total cost of an adult nonmaternal hospital stay was higher for cancer (USD 22,100) than in comparison to other principal diagnoses ($13,800).
The most prevalent principal cancer diagnoses were colorectal cancer, secondary malignancies, and respiratory cancers. These cancers had accounted for more than one-third of the total aggregate cost of hospital stays especially for cancer.
North America possessed the largest proportion of the Metastatic Breast Cancer Treatment Market share
Based on the region, North America held the maximum market share of metastatic breast cancer treatment of about 46.72% in 2020. It is primarily due to the rise in healthcare investment, backed up by prominent healthcare service providers, and the growing prevalence of cancer in the entire region. In addition, countries in North America, like the United States, Canada, and Mexico, are investing in spreading breast cancer awareness programs, which is projected to contribute to the regional market growth. Also, with the rise in cancer cases, the need for metastatic breast cancer therapy in North American countries is likely to rise exponentially. As per the Breast Cancer Organization's data, as of January 2022, Breast cancer had impacted more than 3.8 million American women. According to statistics, breast cancer is expected to account for nearly 30% of newly diagnosed cancers cases among women in 2022. Moreover, the APAC region is expected to develop at the fastest CAGR over the forecasted period due to increased prevalence of breast cancer and the rise in the geriatric population in the entire region,
Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.
https://www.strategicmarketresearch.com/pre-order-enquiry/metastatic-breast-cancer-treatment-market
The leading market players that are covered in the Global Metastatic Breast Cancer Treatment Market report are:
- Gilead Sciences
- AstraZeneca
- Bayer
- Sun Pharmaceutical
- Eli Lilly
- Pfizer
- Novartis
- Merck
- Roche
- GlaxoSmithKline
- Johnson & Johnson
Kindly go through and get access to our comprehensive coverage of myriad number of Healthcare reports published in the last three months:
https://www.strategicmarketresearch.com/reports/healthcare
Global Metastatic Breast Cancer Treatment Market: Recent Developments
- On 27th April 2022, AstraZeneca and Daiichi Sankyo's Enhertu were granted Breakthrough Therapy Designation (BTD) in the United States to cure adult patients with unresectable or metastatic HER2-low breast cancer who have got a prior systemic therapy in the metastatic setting.
- On 13th October 2021, a group of Canadian researchers at Sunnybrook Health Sciences Centre successfully demonstrated the magnetic resonance (MR)-guided focused ultrasound that can be used to safely conduct the antibody therapeutic treatment to breast cancer that has already spread to the brain.
- On 7th April 2021, sacituzumab govitecan successfully received the FDA approval to treat patients suffering from metastatic triple-negative breast cancer who have already undergone 2 or more prior systemic treatments, out of which at least one was for metastatic illness. On the other hand, sacituzumab govitecan also got approval in April 2020 for the patients with mTNBC who previously underwent at least two treatments for metastatic disorders.
Related Reports
The vital report on "Cancer/Tumor Profiling Market" Insights & Forecast 2030 published by Strategic Market Research delivers a clear-cut idea of the key market insights. The market was valued at 8.57 Billion in 2020, and it's estimated to increase to a 19.91Billion by 2028 with a decent CAGR of 11.87%. The most crucial drivers of this market are the rise in the implementations of OMICs (genomics, proteomics, metabolomics, and epigenetics) to build personalized medicines for cancer management and the increase in the prevalence of several methods of cancer tests throughout the globe. The key players are Illumina Inc, NeoGenomics Laboratories Inc, QIAGEN N.V., Genomic Health Inc, Caris Life Sciences, HTG Molecular Diagnostics Inc, Helomics Corporation, Sysmex Corporation, Ribomed Biotechnologies Inc, NanoString Technologies Inc, Guardant Health Inc, Roche Diagnostics, GenScript Biotech Corporation, Tempus Labs, Boreal Genomics Inc, Perthera, Agendia, Omniseq, and Histogene X.
Breast Cancer Liquid Biopsy Market
The vital report on "Breast Cancer Liquid Biopsy Market" Insights & Forecast 2030 published by Strategic Market Research asserts a concrete understanding of pivotal market insights. The market was valued at 104.42 Million in 2020, and it's assumed to grow up to 604.71 Million by 2030 with a decent CAGR of 19.2%.The surge in the funding for R&D in breast liquid biopsy, the increase in the favorable initiatives undertaken by global health organizations and governments, and the rise in the approvals for breast cancer liquid biopsy reagents are augmenting the market's overall growth. The key players in the Global Breast Cancer Liquid Biopsy Market are Johnson & Johnson (Janssen Diagnostics), F. Hoffmann-La Roche Ltd, Qiagen, Janssen, Diagnostics, Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences Inc., Biodesix, Illumina Inc., Bio-Rad Laboratories, BioceptInc,)
The vital report on "Metabolomics Market" Insights & Forecast 2030 published by Strategic Market Research explains a detailed understanding of the crucial market insights. The market was valued at 1.9Billion in 2020, and it's forecasted to reach a landmark of up to a 6.68Billion by 2030 with a comprehensive CAGR value of 13.4%. The rise in the private and government investments in the metabolomics market for the research and development and the increase in life-threatening diseases like cancer & cardiovascular diseases are the primary drivers of the Metabolomics Market. Some of the pertinent players operating in the Metabolomics market include Waters Corporation, Merck KGaA, GE Healthcare, Hitachi High-Technologies Corporation, Human Metabolome Technologies, Inc., LECO Corporation, Metabolon, Inc., Bio-Rad Laboratories, Agilent Technologies, Shimadzu Corporation, Thermo Fisher Scientific, Danaher Corporation, Bruker Corporation, PerkinElmer, Scion Instruments, DANI Instruments S.p.A., GL Sciences, SRI Instruments, Kore Technology Ltd., JASCO, Inc.
The vital report on "Hemodynamic Monitoring Market" Insights & Forecast 2030 published by Strategic Market Research exaggerates a well-developed idea regarding the different market insights. The market was valued at 506.8 Million in 2021, and it's anticipated to grow up to 2.37 billion by 2030 with a CAGR of 5.3%. Technological enhancements in hemodynamic monitoring systems, increasing prevalence of cardiovascular diseases & diabetes, the surge in the geriatric population & rising number of surgeries are the primary amplifiers that propel the market forward. The most vital players in the Global Hemodynamic Monitoring Market are SchwarzerCardiotek GmbH, Tensys Medical Inc., Koninklijke Philips NV, LiDCO Group PLC, GE Healthcare, Edwards Lifesciences Corporation, Getting AB, ICU Medical Inc., Baxter (Cheetah Medical Inc.)
The vital report on "Live Cell Imaging Market" Insights & Forecast 2030 published by Strategic Market Research encompasses a transparent understanding of the various market insights. The market was valued at 1.8 Billion in 2020, and it's poised to grow up to 4.18Billion by 2030 with an overall CAGR of 8.8%. The rise in the adoption of high-content screening techniques in drug discovery is the primary driver of this Live Cell Imaging Market. Some of the key players are Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc., CytoSMART Technologies, NanoEnTek Inc., Phase Focus Limited, Tomocube Inc., Phase Holographic Imaging PHI AB, B.D. Biosciences, Sony Biotechnology Inc., Merck KGaA, KEYENCE Corporation, ibidi GmbH, Bio-Rad Laboratories, Logos Biosystems, and Nanolive SA.
About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup that is in the Introduction stage of the Product Life cycle or an established one that is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis, or new geographical penetration and expansion.
Contact Us:
Strategic Market Research LLP.
Sunil Kumar
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Press Release: https://www.strategicmarketresearch.com/press-releases
Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/
